TP53 and hepatocellular carcinoma: A single trial investigated a combination of Ad-p53 with oral pembrolizumab in patients with unresectable, refractory liver metastases of colorectal carcinoma (CRC) and other solid tumors, including primary hepatocellular carcinoma (HCC), and an additional solution of Ad-p53 combined with nivolumab in recurrent head and neck squamous cell cancer (HNSCC) was terminated.